• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Cynosure’s Q1 earnings miss expectations

Cynosure’s Q1 earnings miss expectations

May 2, 2013 By Sony Salzman

First-quarter sales for Cynosure (NSDQ:CYNO) may have grown by a healthy 19%, but investors still sent share prices down some 2.2% today after the medical aesthetics company missed Wall Street’s expectations by 1 thin dime.

Westford, Mass.-based Cynosure posted profits of $1.2 million, or 7¢ per share, on sales of $40.7 million during the 3 months ended March 31, for profit growth of 51.3% and a top-line increase of 51.3%.

Still, adjusted to exclude 1-time items, earnings per share were 12¢, a full 10¢ below expectations on The Street. CYNO shares closed down 2.2% at $25.30 apiece today.

The adjusted numbers included $1.1 million in costs from Cynosure’s $294 million buyout of Palomar Medical (NSDQ:PMTI), according to a press release.

"We expect our pending acquisition of Palomar Medical Technologies to close by the end of June 2013," CEO Michael Davin said in prepared remarks. "The transaction would complement and broaden our product lineup with the addition of Palomar’s diode and intense pulsed light fractional aesthetic systems, would double the number of patents in our portfolio and would enhance our global distribution network."

 

Filed Under: Cosmetic/Aesthetic, MassDevice Earnings Roundup, News Well Tagged With: 2013, Cynosure Inc., Palomar Medical Technologies Inc., Q1

More recent news

  • Imperative Care, Proximie partner to develop surgical robot to treat stroke
  • Carlsmed launches IPO roadshow
  • Varian introduces IntelliBlate for image-guided cancer therapy in Europe
  • Henry Schein CEO Stanley M. Bergman to retire
  • Medtronic wins CE mark for LigaSure sealing tech for Hugo surgical robot

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy